Compare Organon & Co. Common Stock (OGN) vs Pacific Gas & Electric Co. Common Stock (PCG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Pacific Gas & Electric Co. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Pacific Gas & Electric Co. Common Stock trades at $13.24 (market cap $40.02B). The key difference: Pacific Gas & Electric Co. Common Stock is far larger — about 11.1× Organon & Co. Common Stock's market cap, and Pacific Gas & Electric Co. Common Stock pays the higher dividend (1.5%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Pacific Gas & Electric Co. Common Stock for 6 Days on average.
| OGN | PCG | |
|---|---|---|
Market Cap | $3.62B | $40.02B |
Volume | 2,892,999 | 38,222,102 |
Sector | Health | Utilities |
52-Week High | $13.81 | $19.11 |
52-Week Low | $5.70 | $11.95 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $105.33B |
Dividend Yield | 0.58% | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PCG trades at $13.33, up 1.29% with a bullish technical signal despite mixed momentum indicators. The stock shows strong fundamentals with a P/E of 9.59 and net income margin of 12.25%, supported by recent earnings beats. Recent news highlights PG&E's proactive wildfire safety measures and strategic initiatives, including a 10-year undergrounding plan to mitigate risks. Analyst consensus remains positive with a $18.22 price target, though technical indicators show some overbought conditions.
PCG presents a value opportunity with attractive valuation metrics and improving profitability, but faces significant wildfire-related risks and regulatory uncertainty. The stock's upside potential depends on successful execution of safety initiatives and favorable regulatory outcomes, making it suitable for risk-tolerant investors seeking utility exposure with growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Pacific Gas & Electric Co. Common Stock
PG&E Corporation is the parent company of Pacific Gas and Electric Company, a utility serving Northern and Central California. Its main business is the sale and delivery of electricity and natural gas.
Read more on PCG →
